Cyclo Therapeutics Inc (CYTH)

[John Bates]

Any commencement of a clinical trial should provide enough attention to get it over a buck. One would have to watch out for that rogue analyst, Adam Fuerstein (sp?), after that, but periodic runs to the mid-upper 1's could happen without any news.

At the moment, it doesn't look like actual sales will ever be a priority, but you never know.